Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents
暂无分享,去创建一个
Robert O'Connor | Paul Dowling | Martin Clynes | L. O’Driscoll | M. Clynes | P. Dowling | R. O'connor | Lorraine O'Driscoll | N. O'Donovan | Norma O'Donovan | R. O’Connor | R. O'Connor
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] A. Scott,et al. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity , 2005, Clinical Cancer Research.
[3] G. Hortobagyi,et al. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins , 2004, British Journal of Cancer.
[4] A. Protopopov,et al. The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.
[5] Roman Rouzier,et al. Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma , 2005, Cancer.
[6] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[7] M. Piccart,et al. Progress and new standards of care in the management of HER-2 positive breast cancer. , 2007, European journal of cancer.
[8] G. Tusnády,et al. Membrane topology of human ABC proteins , 2006, FEBS letters.
[9] N. Munshi,et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. , 2006, European journal of cancer.
[10] D. Botstein,et al. A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.
[11] R. Nahta,et al. Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.
[12] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[13] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[14] S. Abdulkadir,et al. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance , 2004, Oncogene.
[15] E. Moran,et al. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. , 1997, Biochemical pharmacology.
[16] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[17] Maria Kavallaris,et al. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia – An in vivo study , 2006, Proteomics.
[18] R. Nicholson,et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.
[19] R. Callaghan,et al. The translocation mechanism of P‐glycoprotein , 2006, FEBS letters.
[20] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[21] J. Zalcberg,et al. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.
[22] F. Cappuzzo,et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. Clarke,et al. ATP binding cassette transporters and drug resistance in breast cancer. , 2003, Endocrine-related cancer.
[24] R. Kerbel,et al. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. , 2004, International journal of radiation oncology, biology, physics.
[25] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[27] C. Sotiriou,et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer , 2002, Breast Cancer Research.
[28] S. Bates,et al. ABC transporters and inhibitors: new targets, new agents. , 2002, Current opinion in investigational drugs.
[29] T Tanaka,et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. , 2001, Cancer research.
[30] M. Bittner,et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.
[31] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[32] T. Fojo,et al. The role of ABC transporters in clinical practice. , 2003, The oncologist.
[33] C. la Vecchia,et al. Diverging trends in breast cancer mortality within Switzerland. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[35] Asad U. Khan,et al. Ribozyme: a clinical tool. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[36] Paolo Valerio,et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. , 2006, Current medicinal chemistry.
[37] R. Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .
[38] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[39] W. Gradishar,et al. Gene expression in breast cancer , 2006, Current treatment options in oncology.
[40] B. Sarkadi,et al. ABCG2 – a transporter for all seasons , 2004, FEBS letters.
[41] G. Qiao,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .
[42] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[43] B. Trock,et al. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. , 2005, Seminars in oncology.
[44] M. Pirmohamed,et al. hOCT 1 and resistance to imatinib. , 2005, Blood.
[45] P. Borst,et al. Multidrug resistance-associated proteins 3, 4, and 5 , 2007, Pflügers Archiv - European Journal of Physiology.
[46] B. Druker,et al. STI571 as a Targeted Therapy for CML , 2003, Cancer investigation.
[47] F. de Longueville,et al. Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes , 2004, Cancer Research.
[48] Edward S. Kim,et al. Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib , 2007, Clinical Cancer Research.
[49] A. Isaksson,et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles , 2005, British Journal of Cancer.
[50] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[51] Mariël Brok,et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.
[52] W. Berger,et al. Cellular functions of vaults and their involvement in multidrug resistance. , 2006, Current drug targets.
[53] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[54] M. Pollak,et al. Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells , 2004, International journal of cancer.
[55] Y. S. Kim,et al. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. , 2004, Cancer letters.
[56] P. Houghton,et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. , 2006, Cancer research.
[57] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[58] P. Hegde,et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[59] M. Clynes,et al. RNA Interference with siRNA. , 2006, Cancer genomics & proteomics.
[60] M. Gottesman,et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[61] B. Sarkadi,et al. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[62] D. Keppler,et al. Detection of the Human Organic Anion Transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in Liver and Hepatocellular Carcinoma , 2003, Laboratory Investigation.
[63] Yaming Su,et al. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. , 2004, Molecular pharmaceutics.
[64] R. O'connor,et al. The pharmacology of cancer resistance. , 2007, Anticancer research.
[65] J. Mesirov,et al. Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[66] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[67] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[68] Naoto T Ueno,et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. , 2004, Cancer research.
[69] A. Vlahou,et al. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. , 2005, Oncology reports.
[70] Naoto T. Ueno,et al. P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.
[71] I. Fichtner,et al. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance , 2006, Proteomics.
[72] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[73] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[74] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[75] H. Tsuda,et al. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. , 2006, Oncology reports.
[76] J. Stec,et al. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer , 2002, Cancer journal.
[77] R. Pérez-Tomás,et al. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.
[78] I. Ghobrial,et al. New Frontiers in the Treatment of Multiple Myeloma , 2006, TheScientificWorldJournal.
[79] U. Zangemeister‐Wittke,et al. Antisense molecules for targeted cancer therapy. , 2006, Critical reviews in oncology/hematology.
[80] J. Reis-Filho,et al. The impact of expression profiling on prognostic and predictive testing in breast cancer , 2006, Journal of Clinical Pathology.
[81] A. Sparreboom,et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.
[82] D. Chauhan,et al. A novel proteasome inhibitor NPI-0052 as an anticancer therapy , 2006, British Journal of Cancer.
[83] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[84] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] T. Fojo,et al. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. , 2004, Current drug targets.
[86] L. O’Driscoll,et al. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer , 2006, Cancer Chemotherapy and Pharmacology.
[87] R. Kim,et al. Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition , 2003, European journal of clinical investigation.
[88] Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. , 2005 .
[89] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] Chava Kimchi-Sarfaty,et al. P-glycoprotein: from genomics to mechanism , 2003, Oncogene.
[91] P. L. Bergsagel,et al. Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.
[92] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[93] C. Perou,et al. Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.
[94] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[95] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[96] Y. Hathout,et al. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. , 2004, Journal of proteome research.
[97] Biaoyang Lin,et al. Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression Levels*S , 2006, Molecular & Cellular Proteomics.
[98] N. Seki,et al. Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. , 2005, Oncology Report.
[99] R. Gust,et al. Dinuclear Alkylamine Platinum(II) Complexes of [1,2‐Bis(4‐fluorophenyl)ethylenediamine]platinum(II): Influence of Endocytosis and Copper and Organic Cation Transport Systems on Cellular Uptake , 2006, ChemMedChem.
[100] L. O’Driscoll,et al. Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance , 1997, International journal of cancer.
[101] Zhe-Sheng Chen,et al. ABCC10, ABCC11, and ABCC12 , 2007, Pflügers Archiv - European Journal of Physiology.
[102] D. Steinemann,et al. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. , 2005, Cancer genetics and cytogenetics.
[103] Kenneth C Anderson,et al. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. , 2007, Experimental hematology.
[104] J. Harbott,et al. Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance , 2006, Leukemia.
[105] Gema Moreno-Bueno,et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5‐Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53 , 2006, International journal of cancer.
[106] S. Cole,et al. Transport of glutathione and glutathione conjugates by MRP1. , 2006, Trends in pharmacological sciences.